Legal Representation
Attorney
R. Lee Fraley
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 9, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Nov 19, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 8, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 8, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 18, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 29, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 29, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 29, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 29, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 29, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jul 15, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 15, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 15, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 21, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 21, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 21, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 10, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 10, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 10, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 9, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 10, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 12, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Software as a service (SAAS) services featuring software to aggregate and process data, generate and share information and reports in the field of pharmaceuticals, and provide advanced predictive analytics to support patient accessibility to pharmaceuticals, pharmaceutical contracting, patient services insights, and medication payer insights, and commercial operations for pharmaceutical companies for use in developing strategies for commercialization of products and services within the field of biopharmaceuticals
Additional Information
Other
as to "RX" has become distinctive of the goods/services through the applicant's substantially exclusive and continuous use of the mark in commerce that the U.S. Congress may lawfully regulate for at least the five years immediately before the date of this statement.
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"RX"